Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Abbott (NYSE: ABT) today announced that the U.S. District Court for the Western District of Michigan has amended the recent consent decree allowing...
Data presented at EuroPCR 2022 reinforce the impact of Abbott's minimally invasive heart devices on patient outcomes and quality of life Findings...
Abbott (NYSE: ABT) has agreed to enter into a consent decree with the U.S. Food and Drug Administration (FDA) related to its Sturgis, Mich., infant...
Abbott (NYSE: ABT) today announced a new partnership with Women as One to launch a new program designed to train more female and underrepresented...
Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity™ m system, which provides fast results in high volumes –...
At the request of the U.S. Food and Drug Administration (FDA), Abbott (NYSE: ABT) is releasing limited quantities of metabolic nutrition formulas...
Abbott (NYSE: ABT) today announced results from the PERSIST-END study, which showed that nearly nine out of 10 patients (89%) treated for persistent...
Abbott (NYSE: ABT) today announced U.S. availability of its Amplatzer™ Steerable Delivery Sheath, which is used with the company's Amplatzer Amulet™...
Meta-analysis of 75 real-world studies found that Abbott's FreeStyle Libre system is associated with significant reductions in glycated hemoglobin...
Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin...
Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation (TRC) to purchase up to 1,000,000 Abbott ...
Abbott (NYSE: ABT) today announced that it has launched an upgraded version of its NeuroSphere™ myPath™ digital health app with enhanced...
...
Abbott's Aveir single chamber (VR) pacing system is the world's only leadless pacemaker with a unique mapping capability to assess correct...
Abbott (NYSE: ABT) and the Local Initiatives Support Corporation (LISC) announced a $37.5 million initiative to provide diverse small businesses with ...
Abbott (NYSE: ABT) will announce its first-quarter 2022 financial results on Wednesday, April 20, 2022, before the market opens. The announcement...
Abbott (NYSE: ABT) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the expansion of reimbursement coverage for...
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the company's CardioMEMS™ ...
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 47 cents per share. Abbott has increased its dividend...
Abbott (NYSE: ABT) is initiating a proactive, voluntary recall of powder formulas, including Similac, Alimentum and EleCare manufactured in Sturgis,...
Abbott (NYSE: ABT) today announced the world's first patient implants of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i™...
Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2021, and issued its financial outlook for...
Abbott (NYSE: ABT) today announced it has received clearance from the U.S. Food and Drug Administration for the EnSite™ X EP System with EnSite...
A Abbott é a primeira empresa de cuidados para saúde a estar no palco principal do evento de tecnologia mais influente do mundo, fazendo história na...
Abbott hizo historia en el evento CES y presentó un discurso de apertura en el evento tecnológico más influyente del mundo; es la primera empresa del ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.